MedTrace Logo

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

NCT06980597 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-05-20

No results posted yet for this study

Summary

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Idiopathic Inflammatory Myopathy (IIM)
  • Systemic Sclerosis (SSc)
  • ANCA Associated Vasculitis (AAV)

Interventions

BIOLOGICAL

OL-108

OL-108 will be given through IV bolus with ascending dose levels to determine the maximum tolerated dose (MTD)

Sponsors & Collaborators

  • Beijing GoBroad Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06980597 on ClinicalTrials.gov